Properties (42)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
gptkb:carbamazepine
|
| gptkbp:brand |
gptkb:Carbatrol
gptkb:Equetro Tegretol |
| gptkbp:clinicalTrials |
Phase IV
|
| gptkbp:contraindication |
hypersensitivity to carbamazepine
bone_marrow_suppression |
| gptkbp:date |
1990
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:endOfLife |
25 to 65 hours
|
| gptkbp:formulation |
extended-release tablet
|
| gptkbp:gestationPeriod |
D
|
| gptkbp:healthcare |
avoid alcohol
take with food regular follow-up appointments report any rash immediately do not stop abruptly |
| https://www.w3.org/2000/01/rdf-schema#label |
Tegretol XR
|
| gptkbp:interactsWith |
gptkb:MAO_inhibitors
oral contraceptives warfarin |
| gptkbp:is_monitored_by |
CBC
liver function tests renal function tests |
| gptkbp:mandates |
partial seizures
generalized_tonic-clonic_seizures mixed_seizure_disorders |
| gptkbp:manufacturer |
Novartis
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
nausea drowsiness blurred vision |
| gptkbp:skills |
100 mg
400 mg 200 mg |
| gptkbp:triggerType |
sodium channel blocker
|
| gptkbp:usedFor |
treating epilepsy
treating bipolar disorder treating trigeminal neuralgia |
| gptkbp:waterManagement |
urine
|